FDA to Hold Webinar on the Updated “Healthy” Claim
Webinar on the Final Rule on the Definition of Term “Healthy” on food labels
Related Articles
Not enough hospitals are testing their predictive AI models for accuracy, bias, study finds
Many U.S. | Only 61% of hospitals using AI or a predictive model report evaluating for accuracy using local data, and just 44% do so…
FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer – MedCity News
AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved…
Anti–immune complex antibodies are elicited during repeated immunization with HIV Env immunogens
Polyclonal epitope mapping reveals anti–immune complex antibodies that target idiotopes on antibodies bound to HIV Env.
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study – Beyond the Abstract
Testicular Cancer, Robotic Postchemotherapy, Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND), IGCCCG classification, minimally invasive techniques for Testicular Cancer.
FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult…
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult…
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult…
Florida hospital CEO says Medicare site-neutral payment reform ‘makes some sense’
Tens of billions of dollars in hospital revenue could be at stake if Medicare cuts payments for outpatient care.
